PF-04929113
|
|
|
- CAS-Nr.
- 908115-27-5
- Englisch Name:
- PF-04929113
- Synonyma:
- CS-33;snx54227;SNX-5422;PF-04929113;PF-04929113, >=98%;PF04929113 SNX-54227;PF-04929113(SNX5422);snx5422 PF 04929113;PF-04929113 USP/EP/BP;PF-04929113 SNX-5422 PF04929113 SNX5422
- CBNumber:
- CB52561489
- Summenformel:
- C25H30F3N5O4
- Molgewicht:
- 521.53
- MOL-Datei:
- 908115-27-5.mol
|
PF-04929113 Eigenschaften
- Schmelzpunkt:
- 298-299℃
- Siedepunkt:
- 646.5±55.0 °C(Predicted)
- Dichte
- 1.48
- storage temp.
- Store at -20°C
- Löslichkeit
- ≥23.85 mg/mL in DMSO with gentle warming; insoluble in H2O; insoluble in EtOH
- Aggregatzustand
- solid
- pka
- 15.07±0.50(Predicted)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
PF-04929113 Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
PF 04929113 can be used in pharmacological activity and therapeutic use in therapeutic breast cancer drug target for multiclass comparative virtual screening to identify novel Hsp90 inhibitors. HSP90
Enzyminhibitor
This potent and selective HSP90 inhibitor (FW = 521.54 g/mol; CAS 908115-27-5; Solubility: 100 mg/mL DMSO, <1mg/mL H2O), also knownas SNX-5422 and (1R,4R)-4-(2-carbamoyl-5-(6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl)phenylamino)cyclohexyl 2- aminoacetate, targets heat shock protein-90 (Kd = 41 nM) and also inhibits Her-2 degradation (IC50 = 37 nM). PF-04929113 also shows potent antiproliferative activity against a broad range of cancer cell types, e.g. MCF-7 (IC50 =16 nM), SW620 (IC50 =19 nM), K562 (IC50 =23 nM), SK-MEL-5 (IC50 =25 nM), and A375 (IC50 =51 nM). SNX2112 inhibits in vitro proliferation, inducing G2/M arrest, and enhanced cytotoxicity, chemosensitivity, and radiosensitivity between 25 and 250 nM, decreasing expression and/or phosphorylation of EGFR, c-MET, AKT, ERK-1 and -2, IκB kinase, and STAT3, corresponding downstream NFκB, AP-1, and STAT3 reporter genes, and target oncogenes and angiogenic cytokines.
PF-04929113 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
PF-04929113 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 92)Lieferanten
908115-27-5()Verwandte Suche:
- (1r,4r)-4-(2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl)phenylamino)cyclohexyl 2-aminoacetate
- PF-04929113, >=98%
- snx54227
- PF04929113 SNX-54227
- PF-04929113
- SNX-5422
- PF-04929113(SNX5422)
- Glycine trans-4-[[2-(aminocarbonyl)-5-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]phenyl]amino]cyclohexyl ester
- CS-33
- SNX5422;PF 04929113;SNX 5422;PF-04929113;
- (1r,4r)-4-((2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)cyclohexyl 2-aminoacetate
- trans-4-([2-(Aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl] phenyl]amino)cyclohexyl glycinate
- snx5422 PF 04929113
- PF-04929113 USP/EP/BP
- trans-4-((2-Carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)cyclohexyl 2-aminoacetate
- PF-04929113 SNX-5422 PF04929113 SNX5422
- 908115-27-5
- C25H30F3N5O4
- Inhibitors
- Inhibitor
